"New" Augmentin

GSK expects approval in 2001 for both the sustained-release formulation of amoxicillin/clavulanate in a 16:1 concentration and the pediatric "extra strength" 14:1 formulation, Senior VP-New Product Development Palmer says. The NDA for Augmentin SR was filed in late December, while Augmentin ES was filed in 1997 and was reviewed by an FDA advisory committee in January (1"The Pink Sheet" Feb. 5, p. 6)